Abbott’s confirm Rx smartphone compatible ICM offers more accurate detection of arrhythmia

Abbott launched a smartphone-compatible next-gen insertable cardiac monitor (ICM) called Confirm Rx™ for more accurate remote monitoring of unpredictable heart rhythm problems. The small paperclip-sized implantable device offers more accurate detection of arrhythmia than traditional devices.

An arrhythmia is a problem with the rhythm of your heartbeat. The most common type of arrhythmia is atrial fibrillation, which causes an irregular and fast heartbeat. For the 33.5 million people living with atrial fibrillation (AFib)—the most common arrhythmia—many do not even know they have the condition.

The device is inserted just under the skin in the chest above the heart during a quick, minimally invasive outpatient procedure. It is the only ICM on the market that syncs to a smartphone via Bluetooth® and transmits information to the physician to help identify irregular heartbeats quickly. With the mobile app, there’s no need for an additional transmitter. This user-friendly health technology is translated in nearly 40 languages, says a press release.

“Through new advances like Abbott’s next generation of Confirm Rx ICM, physicians can act more proactively and efficiently in their treatment approach, and patients can stay engaged and connected,” said Avi Fischer, M.D., medical director of Abbott’s Cardiac Rhythm Management therapies.

Currently available wearables for tracking cardiac arrhythmias have drawbacks when it comes to making a clinical diagnosis. Some require recharging at night while others require some level of interaction by the person to record symptoms. These may cause inaccurate data being delivered.

“Many of these devices still aren’t leading to improved diagnosis or solving the key clinical challenges for people at risk,” said Sean Beinart, M.D., a cardiologist with Adventist Healthcare in Rockville, Md. “Like a guardian for heart health, Confirm Rx ICM can relay important data about a person’s heart rhythm through their smartphone and alert their care team to a potentially dangerous heart event. With Abbott’s new technology, I can better identify risk—making it actionable for me and life-changing for my patient.”

Source: www.wearable-technologies.com

Related posts

MC10 collaborates with AbbVie for multiple sclerosis clinical trials using BioStamp nPoint system


DARPA funds six organizations to support next-generation nonsurgical neurotechnology program


The Owlet Band monitors your unborn baby while you sleep